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Abstract
 
Many growth factors and cytokines prevent apoptosis. Using an expression cloning method,
we identified a novel antiapoptotic molecule named Anamorsin, which does not show any
homology to known apoptosis regulatory molecules such as Bcl-2 family, caspase family, or
signal transduction molecules. The expression of Anamorsin was completely dependent on
stimulation with growth factors such as interleukin 3, stem cell factor, and thrombopoietin in
factor-dependent hematopoietic cell lines, and forced expression of Anamorsin conferred resis-
tance to apoptosis caused by growth factor deprivation in vitro. Furthermore, Anamorsin was
found to act as an antiapoptotic molecule in vivo because Anamorsin
 
 
 
/
 
  
 
mice die in late gestation
due to defective definitive hematopoiesis in the fetal liver (FL). Although the number of
hematopoietic stem/progenitor cells in the FL did not decrease in these mice, myeloid, and
particularly erythroid colony formation in response to cytokines, was severely disrupted. Also,
Anamorsin
 
 
 
/
 
  
 
erythroid cells initiated apoptosis during terminal maturation. As for the mecha-
nism of Anamorsin-mediated cell survival, a microarray analysis revealed that the expression of
Bcl-xL and Jak2 was severely impaired in the FL of Anamorsin
 
 
 
/
 
  
 
mice. Thus, Anamorsin is
considered to be a necessary molecule for hematopoiesis that mediates antiapoptotic effects of
various cytokines.
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gene targeting
 
Introduction
 
Growth, differentiation, and survival of hematopoietic cells
are positively or negatively regulated by a number of cyto-
kines. Among these factors, several cytokines such as eryth-
ropoietin (EPO), thrombopoietin (TPO), G-CSF, and
stem cell factor (SCF) are considered to play crucial roles in
hematopoiesis because the targeted disruption or spontane-
ous loss of function mutation of these factors or their re-
ceptors leads to severe defects in mutant mice (1–4).
Upon binding to their receptors, cytokines initially
evoke phosphorylation and activation of cell surface tyrosine
kinases such as receptor tyrosine kinases or JAK family tyrosine
kinases. Activated tyrosine kinases transmit mitogenic and
antiapoptotic signals through simultaneous activation of
downstream signaling molecules including Ras/MAPK,
PI3-K/Akt, and signal transducers and activators of tran-
scription (STATs; 5, 6). During the last decade, accumulated
experimental evidence has suggested that each of the Ras/
MAPK, PI3-K, and STATs can mediate both cell growth
and survival. In the case of Ras/MAPK, dominant negative
Ras inhibits IL-3–dependent growth of the murine IL-3–
dependent cell line Ba/F3 (7), and oncogenic Ras enables
Ba/F3 cells to survive under conditions of IL-3 deprivation
(8). In this system, Ras/MAPK was found to induce expres-
sion of antiapoptotic Bcl-2 family members, Bcl-2 and Bcl-xL
(8, 9). However, the induction of these molecules by Ras/
MAPK seems to be indirect and it remains unknown
which molecule(s) are involved in their induction. In addi-
tion, Ras promotes cell survival, at least in part, through
the activation of PI3-K, which is observed in several, but
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not all, cell types (10). The PI3-K/Akt pathway exerts anti-
apoptotic effects by phosphorylating and inhibiting the
function of proapoptotic molecules, BAD and FKHRL1.
Also, the PI3-K/Akt pathway degrades the death effector,
caspase-9 (11). Both Ras/MAPK and PI3-K/Akt pathways
inhibit expression of the proapoptotic Bcl-2 family mem-
ber, Bim, which plays a pivotal role in factor-deprived
apoptosis (12). On the other hand, similarly to oncogenic
Ras, a constitutively active form of STAT5A enables Ba/
F3 cells to proliferate and survive under IL-3–starved con-
ditions (13). Regarding the mechanism of STAT-mediated
cell survival, STAT5 and STAT1 were found to induce the
expression of Bcl-xL mRNA through direct binding to its
promoter as transcription factors (14, 15). Supporting these
findings, hematopoietic cells obtained from STAT5A
 
 
 
/
 
 
 
5B
 
 
 
/
 
  
 
mice were more likely to undergo apoptosis due to a
defect in induction of Bcl-xL (15, 16). Moreover, STAT3
and STAT5 were reported to induce expression of Bcl-2
mRNA, but its induction seems to be indirect (9, 17). Al-
though great advances have been made in understanding
signal transduction pathways mediated by cytokines, several
critical points still remain unelucidated. In particular, it re-
mains largely unknown how Ras/MAPK induces expres-
sion of Bcl-2 family members, and thus it has been specu-
lated that some critical, intermediary signaling molecules
might be missing in this pathway.
Factor-dependent cell lines such as Ba/F3 (pro–B cells),
FL.5.12 (pro–B cells), and 32D (myeloid cells) are useful
tools for analyzing the mechanism of cytokine-dependent
cell growth and survival. Indeed, most previous studies were
performed with these cell lines. Moreover, recent studies
identified two apoptosis regulatory molecules with cDNA
microarray analyses by using FL5.12 cells cultured with or
without IL-3. One is a proapoptotic molecule, 24p3, en-
coding a lipocalin, whose expression is up-regulated after
IL-3 depletion (18). By contrast, the expression of a serine/
threonine kinase, Pim-2, which confers resistance to a vari-
ety of apoptotic stimuli, was down-regulated by IL-3 depri-
vation in a microarray analysis (19). These cell lines have
also been used to evaluate oncogenic properties of unchar-
acterized molecules and find activating mutations of certain
genes. For example, activating mutants of STAT5 and c-
 
mpl
 
were both originally identified as molecules that confer fac-
tor-independent growth and survival of Ba/F3 cells by us-
ing retrovirus-mediated expression cloning (13, 20).
By using a retrovirus expression library prepared from Ba/
F3-Ad, an IL-3–independent sub-line established from Ba/
F3 (unpublished data), we cloned a novel antiapoptotic mol-
ecule, Anamorsin (ana-mors-in was designated to mean an
anti-death molecule in Latin), which can confer resistance to
IL-3 deprivation apoptosis in Ba/F3 cells. In addition to an-
tiapoptotic activities of Anamorsin in in vitro assays, we also
demonstrated its antiapoptotic function in vivo by generat-
ing KO mice. The Anamorsin
 
 
 
/
 
  
 
genotype is lethal at late
gestation due to apoptosis of hematopoietic cells in the fetal
liver (FL). Thus, Anamorsin appears to play a crucial role in
definitive hematopoiesis as an antiapoptotic molecule.
 
Materials and Methods
 
Cell Culture and cDNA Transfection.
 
The murine IL-3–depen-
dent cell lines, Ba/F3 and 32D, were cultured in RPMI 1640 sup-
plemented with 10% FCS in the presence of 0.1 ng/ml mIL-3 (Ki-
rin Brewery Company). EPO receptor, c-kit, and c-mpl were
individually engineered to be expressed in Ba/F3 cells, and their
clones were able to proliferate in the presence of the correspond-
ing cytokines. To construct expression vectors for Anamorsin and
H-Ras
 
G12V
 
, these cDNAs were subcloned into pcDNA3 (Invitro-
gen). Ba/F3 cells or 32D cells were transfected with the An-
amorsin or H-Ras
 
G12V 
 
expression vector by electroporation and se-
lected by culturing in media containing 1.0 mg/ml G-418. Out of
several G-418–resistant clones, two clones, in which the transgene
was most intensely expressed, were used for further experiments.
 
DNA Content Analysis.
 
The DNA content of cultured cells
was examined by staining with propidium iodide and then analyzed
on a FACSort™ (Becton Dickinson) as previously described (7).
 
Assays for Caspase-3 Activities.
 
Caspase-3 activities were mea-
sured with the PhiPhiLux-G1D2 kit (OncoImmunin). In this
system, caspase-3 activities are measured by fluorescence that is
derived from the cleaved substrate specific for caspase-3.
 
Northern Blot Analysis.
 
Northern blot analysis was performed
as previously described (21). Membranes were hybridized with
 
32
 
P-labeled Anamorsin probe (nucleotides 255–564 of Anamorsin
cDNA: BamHI fragment) and 
 
 
 
-actin probe (as a loading con-
trol) in rapid hybridization buffer (Amersham Biosciences).
 
Anti-Anamorsin mAbs.
 
Three kinds of rat mAbs against mu-
rine Anamorsin (named KM3048, KM3052, and KM3056) were
generated according to methods previously described (22). The
sequences of the synthesized peptide antigens were CLFLKEPVE-
TAEVNNDKMKTASKL (Anamorsin 1, amino acid residues
92–115), CRVTGKKPNFEVGSSSQ (Anamorsin 2, amino acid
residues 158–173), and CGLAEELEREQSKAQSSQPKSA
(Anamorsin 3, amino acid residues 249–270), respectively. All an-
tibodies used were appropriate for immunoblotting, immunopre-
cipitation, and immunofluorescence staining.
 
Immunofluorescence Staining.
 
Ba/F3 cells were attached to Si-
lane-coated slide glasses (DakoCytomation) by cytospin centrifu-
gation (Shandon, Inc.). Cytospin preparations were fixed with
methanol at 4
 
 
 
C for 10 min, washed three times in PBS, blocked
in PBS containing 1% BSA and 10% mouse serum for 30 min,
and then incubated with 10 
 
 
 
g/ml of an anti-Anamorsin mAb
for 1 h. These slides were next incubated with FITC-conjugated
goat anti–rat IgG (1:50 dilution; ICN Biomedicals) for 1 h,
washed twice in PBS containing 0.2 
 
 
 
g/ml DAPI, and observed
by fluorescent microscopy.
 
Lac-inducible System.
 
To express the dominant negative
H-Ras gene (H-Ras
 
S17N
 
), we used a LacSwitch II–inducible ex-
pression system (Stratagene) as previously described (7). In this
system, isopropyl-
 
 
 
-D-thiogalactopyranoside (IPTG) is added to
the culture medium causing the Lac repressor to be released from
the lactose operon and transcription of the targeted cDNA (H-
Ras
 
S17N 
 
in this case) is initiated.
 
Genotypic Analyses.
 
High molecular weight genomic DNA
was extracted from tails or whole embryos, digested with SacI,
and subjected to electrophoresis on 0.8% agarose gels. Southern
blot analysis was performed with a 5
 
  
 
flanking probe. The
sequences of primers used for PCR analysis were as follows: 
 
 
 
,
5
 
 
 
-ACCTTCGGAAAAGTAGTCGGGTGCTCTTAC-3
 
 
 
; 
 
 
 
, 5
 
 
 
-
CGCATCGCCTTCTATCGCCTTCTTGACGAG-3
 
 
 
; 
 
 
 
, 5
 
 
 
-
GTGTCTAAAACCCATGACCTTTCACCAG-3
 
 
 
. Genomic
DNA from the wild-type allele yields a 310-bp fragment with a 
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primer pair 
 
 
 
/
 
 
 
, and that from the targeted allele yields a 730-bp
fragment with primer pair 
 
 
 
/
 
 
 
.
 
Treatments of the Embryos.
 
Embryos of the stated age were
dissected free of maternal tissues and photographed, and then
fixed in 10% buffered formalin and embedded in paraffin. 4-
 
 
 
m
thick sections were cut and stained. Cell suspensions were iso-
lated from FLs and subjected to flow cytometric analysis, mor-
phologic analysis of cytospin preparations, and methylcellulose
colony assay analysis.
 
Colony Assays.
 
10
 
4 
 
FL cells were obtained from Anamorsin
 
 
 
/
 
 
 
(
 
n 
 
  
 
10), Anamorsin
 
 
 
/
 
  
 
(
 
n 
 
  
 
36), and Anamorsin
 
 
 
/
 
  
 
(
 
n 
 
  
 
11)
embryos at E14.5, and cultured in methylcellulose medium con-
taining the cytokine cocktail, SCF, IL-3, IL-6, and EPO (Metho-
Cult; StemCell Technologies Inc.). The numbers of hematopoi-
etic colonies were counted under phase contrast light microscopy
after 8 d in culture. Also, 10
 
5 
 
FL cells isolated from Anamorsin
 
 
 
/
 
 
 
(
 
n 
 
  
 
11), Anamorsin
 
 
 
/
 
  
 
(
 
n 
 
  
 
40), and Anamorsin
 
 
 
/
 
  
 
(
 
n 
 
  
 
6) em-
bryos at E14.5 were cultured with SCF and EPO for 8 d, and the
numbers of burst-forming unit-erythroid (BFU-E) colonies were
counted.
 
Flow Cytometry Analysis.
 
5 
 
  
 
10
 
5 
 
cells were incubated with 2
 
 
 
l avidin-conjugated anti–mouse Ter-119 mAb (BD Biosciences;
reference 23) at 4
 
 
 
C for 30 min and washed twice in PBS. Cells
were incubated with 2 
 
 
 
l biotin-PE (Becton Dickinson) and an-
nexin V–FITC (Immunotech; reference 24) at 4
 
 
 
C for 30 min,
washed twice in PBS, and then analyzed on a FACSort™ (Becton
Dickinson). Cells were also stained with PE-conjugated anti–
mouse CD44 mAb (BD Biosciences). For CD34, c-kit, and Ter-
119 staining, cells were first incubated with rat anti–mouse CD34
mAb (Caltag Laboratories), biotin-conjugated rat anti–mouse
c-kit mAb (Immunotech), or avidin-conjugated anti–mouse Ter-
119 mAb, and then incubated with FITC-conjugated anti–rat IgG
(BD Biosciences), streptavidin-PE (Becton Dickinson), or biotin-
FITC (Becton Dickinson), respectively. Appropriate isotype con-
trol antibodies were used. Cell surface expression of the different
markers were analyzed on a FACSort™ (Becton Dickinson).
 
Immunoblotting.
 
Isolation of total cellular lysates, gel electro-
phoresis, and immunoblotting were performed according to
methods previously described (25). In brief, the embryo limbs
were lysed in lysis buffer containing protease and phosphatase in-
hibitors. Insoluble fractions were removed by centrifugation.
Whole cell lysates were separated by SDS-PAGE and transferred
to PVDF membrane (Immobilon; Millipore). Membranes were
blocked in TBS-T with 2% BSA for 1.5 h and incubated with 10
 
 
 
g/ml of an anti-Anamorsin mAb for 1.5 h. Immunoreactive
proteins were visualized by a horseradish peroxidase–conjugated
anti–rat IgG Ab with ECL system (Amersham Biosciences). To
reprobe with an anti-GAPDH Ab (American Research Prod-
ucts), membranes were incubated in stripping buffer at 70
 
 
 
C for
1 h, washed, and reused.
 
cDNA Microarray Analysis.
 
We performed a cDNA microar-
ray analysis with IntelliGene II Mouse CHIP (TaKaRa Shuzo
Co.). In brief, poly(A)
 
  
 
mRNA was prepared from total RNA
using Oligotex-dT30 Super mRNA Purification Kit (TaKaRa
Shuzo Co.). 1-
 
 
 
g aliquots of mRNA from E14.5 Anamorsin
 
 
 
/
 
 
 
and Anamorsin
 
 
 
/
 
  
 
FL cells were labeled with Cy3-dUTP and
Cy5-dUTP (Amersham Biosciences), respectively, using an
RNA Fluorescence Labeling Core Kit (M-MLV version;
TaKaRa Shuzo Co.). Labeled probes were mixed with hybridiza-
tion solution (6
 
  
 
SCC, 0.2% SDS, 5
 
  
 
Denhardt’s solution, 0.1
mg/ml denatured salmon sperm DNA). After hybridization for
16 h at 55
 
 
 
C, the slides were washed twice in 2
 
  
 
SSC and 0.1%
SDS for 5 min at 55
 
 
 
C, washed in 2
 
  
 
SSC and 0.1% SDS for 5
 
min at 65
 
 
 
C, and washed in 0.05
 
  
 
SSC for 5 min at room tem-
perature. The slides were scanned using the Affymetrix 428 scan-
ner (Affymetrix, Inc.). The signal intensity of hybridization was
evaluated photometrically by the ImaGene computer program
(BioDiscovery) and normalized to the averaged signals of house-
keeping genes. A cut off value for each expression level was cal-
culated according to the background fluctuation. The fluctuation
can be estimated as the variance of the ratio of Cy5/Cy3.
 
RT-PCR Assays.
 
Total RNA was isolated from E14.5
Anamorsin
 
 
 
/
 
  
 
FL cells and Anamorsin
 
 
 
/
 
  
 
FL cells with TRIsol re-
agent (GIBCO BRL). 1.5 
 
 
 
g total RNA was reverse transcribed to
first strand cDNA with Moloney murine leukemia virus tran-
scriptase (MMLV-RT; Invitrogen) in the presence of dNTPs,
oligo(dT) (Roche), RNasin (Promega), and DTT in a total volume
of 30 
 
 
 
l for 60 min at 42
 
 
 
C, followed by heating for 10 min at
75
 
 
 
C. PCR was performed in a total volume of 50 
 
 
 
l with 5 
 
 
 
l re-
verse-transcribed product, 2.5 U Taq-polymerase, dNTPs, and 0.5
 
 
 
M primers in 1
 
  
 
PCR buffer. The sequences of primer sets are as
follows: Jak2, (sense) 5
 
 
 
-GTTCTTACCGAAGTGCGTGCGA-3
 
 
 
and (antisense) 5
 
 
 
-GGTAATGGTGTGCATCGCAGTT-3 );
Bcl-xL, (sense) 5 -CACTGTGCGTGGAAAGCGTA-3   and
(antisense) 5 -AAAGTGTCCCAGCCGCC-3 ; GAPDH, (sense)
5 -AATGTGTCCGTCGTGGATCTGA-3   and (antisense) 5 -
GATGCCTGCTTCACCACCTTCT-3 .
Online Supplemental Material. Table S1 shows the data of
cDNA microarray analysis concerning the apoptosis-related genes
within IntelliGene II Mouse CHIP. Table S1 is available at http://
www.jem.org/cgi/content/full/jem.20031858/DC1.
Results
Isolation of Anamorsin by Expression Cloning from IL-3–
independent Subline Ba/F3-Ad. We have established a sub-
line named Ba/F3-Ad that can grow and survive under IL-
3–deprived conditions from a murine IL-3–dependent cell
line, Ba/F3 (unpublished data). To identify the molecule(s)
that conferred the observed resistance to factor-deprived
apoptosis on Ba/F3, we performed expression cloning by
constructing a retroviral cDNA library from IL-3–starved
Ba/F3-Ad according to the procedure previously described
(26). In short, we infected the retrovirus library into paren-
tal Ba/F3 (5   105 clones, the average size of the inserts,
1.3 kb; the infection efficacy was estimated to be  35%)
and screened the clones that survived under IL-3–starved
conditions for more than 1 wk and then started to prolifer-
ate in the medium containing IL-3. After isolation of sev-
eral clones that survived under IL-3–deprived conditions,
we isolated the integrated cDNA from genomic DNA ex-
tracted from one clone by the PCR method.
cDNA and Amino Acid Sequence of Anamorsin. By se-
quencing the integrated cDNA, we found that the coding
region of a murine protein, Anamorsin, cDNA consisted of
930 bp (Fig. 1 a). Comparison with a DNA database search
revealed that the sequence of Anamorsin does not exhibit
homology with any known antiapoptotic molecules, in-
cluding Bcl-2 family proteins, caspase inhibitors, or signal
transduction molecules. Also, we found a human homo-
logue of Anamorsin in GenBank data libraries, which re-
vealed 82.6% similarity to murine Anamorsin at the DNA
level and 81.9% similarity at the amino acid level. The hu-A Novel Antiapoptotic Molecule Anamorsin 584
man homologue of Anamorsin was originally found by
Loftus et al. (27) as a molecule with unknown function on
chromosome 16 (sequence data are available from Gen-
Bank/EMBL/DDBJ under accession no. AC004382). An-
amorsin encodes a protein with a molecular weight of  37
kD and the protein sequence database indicates that An-
amorsin has a generic methyltransferase motif around
amino acids 60–99 (Fig. 1 a).
Anamorsin Confers Resistance to Apoptosis Induced by IL-3
Depletion. First, we examined whether Anamorsin was
actually involved in resistance to factor-deprived apoptosis
of Ba/F3-Ad. For this purpose, we stably expressed murine
Anamorsin cDNA in parental Ba/F3 cells and investigated
sensitivity to IL-3–deprived apoptosis. In control Ba/F3
cells, the subdiploid fraction formed from apoptotic cells
emerged as early as 24 h after IL-3 depletion, but this frac-
tion was effectively reduced in Anamorsin-transfected Ba/
F3 cells (percent of apoptotic fraction: control Ba/F3, 37%
at 24 h, 64% at 36 h, and 86% at 48 h; Anamorsin-trans-
fected Ba/F3, 7% at 24 h, 11% at 36 h, and 20% at 48 h;
Fig. 1 b). In agreement with this finding, the activation of
caspase-3, which is detected as a shift in fluorescent inten-
Figure 1. Anamorsin confers
resistance to apoptosis caused by
IL-3 depletion in Ba/F3 cells.
(a) Anamorsin cDNA sequence
and corresponding amino acid
sequence. The underlined amino
acid sequence shows generic
methyltransferase motif. (b and
c) Ba/F3 cells transfected with an
empty vector or Anamorsin
(AM) cDNA were deprived of
IL-3 for the time indicated and
the apoptotic cells were sub-
jected to DNA content analysis
(b) and caspase-3 assays (c).Shibayama et al. 585
sity, was significantly suppressed in Anamorsin-transfected
Ba/F3 cells as compared with that seen in control Ba/F3
cells (Fig. 1 c). However, it should be noted that An-
amorsin alone could not support the growth of Ba/F3 cells
because the number of proliferating cells dramatically de-
creased in Anamorsin-transfected Ba/F3 cells under IL-3–
deprived conditions (percent of the cells in S-G2/M phase
before and after IL-3 depletion: 56% at 0 h vs. 6% at 48 h;
Fig. 1 b, right). Furthermore, Anamorsin-transfected cells
were found to become small and enter G0 phase after IL-3
depletion (unpublished data). We also confirmed that An-
amorsin confers resistance to apoptosis caused by IL-3 de-
pletion in another murine IL-3–dependent cell line, 32D
(unpublished data).
The Expression Profile of Anamorsin and Its Regulation by
Cytokines. Next, we examined the expression profile of
the human Anamorsin homologue in various organs using
MTA panels (CLONTECH Laboratories, Inc.). As shown
in Fig. 2 a, left, the homologue was expressed ubiquitously
in various tissues, with especially high expression levels de-
tected in heart, liver, and pancreas. As for hematopoietic
tissues, the homologue was abundantly expressed in FL and
spleen (Fig. 2 a, right). Also, we found that expression of
Anamorsin was detectable in early stages (7 d) of embryo-
genesis by the PCR method (not depicted).
Because Anamorsin was supposed to exert antiapoptotic
effects in Ba/F3-Ad under IL-3–deprived conditions, we
examined its expression levels in parental Ba/F3 and Ba/
F3-Ad after IL-3 depletion. As expected, Anamorsin was
still expressed in Ba/F3-Ad after 18 h of IL-3 deprivation,
whereas its expression was hardly detectable in parental Ba/
F3 cells (Fig. 2 b, lane 1 vs. 2). However, the addition of
IL-3 recovered expression in parental Ba/F3 cells after 3 h
(Fig. 2 b, lanes 2–7). Next, we investigated whether ex-
pression of Anamorsin was also regulated by other cyto-
kines in Ba/F3 cells. After IL-3 depletion, clones of Ba/F3
that expressed receptors for EPO, SCF (c-Kit), and TPO
(c-Mpl) were cultured with their corresponding cytokines
for the time indicated. As shown in Fig. 2 c, EPO, SCF,
and TPO individually induced expression of Anamorsin as
Figure 2. Anamorsin (AM) was
expressed ubiquitously in various tis-
sues and its expression was induced
by various cytokines through the Ras
signaling pathway. (a) The expres-
sion of the human Anamorsin homo-
logue in various human organs
(MTC panels, CLONTECH Labo-
ratories, Inc.) was examined by
Northern hybridization. (b) Ba/F3
cells were IL-3 depleted for 15–18 h
and then cultured with 0.1 ng/ml
mIL-3 for the time indicated. Induc-
tion of Anamorsin gene was exam-
ined by Northern blot analysis. Ba/
F3-Ad, Ba/F3-Ad in the absence of
IL-3. (c) Ba/F3 cells each transfected
with EPO receptor, c-kit, and c-mpl
were deprived of IL-3 for 15–18 h
and cultured with 5 u/ml mEPO,
100 ng/ml mSCF, and 30 ng/ml
mTPO, respectively, for the time
indicated.  Induction of Anamorsin
gene was examined by Northern blot
analysis. (d) Ba/F3 cells transfected
with an empty vector (Mock) or
oncogenic H-Ras (H-RasG12V) were
deprived of IL-3 for the time indi-
cated. The expression levels of An-
amorsin were examined by Northern
blot analysis. (e) Ba/F3 cells, in
which dominant negative H-Ras
(H-RasS17N) was inducibly expressed
by a LacSwitch-II–inducible expres-
sion system, were cultured with IL-3
in the presence or absence of IPTG
for the time indicated. The expression
levels of Anamorsin were examined
by Northern blot analysis. (f) The
localization of Anamorsin was exam-
ined by an immunofluorescence
staining with an anti-Anamorsin
mAb. Nucleus was visualized with
staining with DAPI. Green, An-
amorsin; blue, nucleus.A Novel Antiapoptotic Molecule Anamorsin 586
efficiently as IL-3, suggesting that expression of Anamorsin
would be regulated by the common signaling molecule(s)
shared by various cytokines. Based on the fact that Ras is
activated by various cytokines and was constitutively acti-
vated in Ba/F3-Ad (unpublished data), we speculated that
Ras might control expression of Anamorsin in Ba/F3 cells.
To examine this possibility, we stably expressed oncogenic
H-Ras (H-RasG12V) in Ba/F3 cells. Also, we prepared a
clone from Ba/F3, in which dominant negative H-Ras (H-
RasS17N) was inducibly expressed by the IPTG treatment.
As expected, the Ba/F3 cells expressing constitutively ac-
tive H-Ras survived under IL-3–starved conditions better
than control Ba/F3 cells. In contrast, the Ba/F3 cells ex-
pressing dominant negative H-Ras died more rapidly after
IL-3 withdrawal than control Ba/F3 cells. In Ba/F3 cells
transfected with H-RasG12V, expression of Anamorsin was
maintained after IL-3 depletion for up to 36 h, whereas its
expression declined to undetectable levels in a mock clone
transfected with empty vector (Fig. 2 d). Furthermore, in-
duced expression of H-RasS17N led to reduction of An-
amorsin expression, even in the presence of IL-3 (Fig. 2 e).
Collectively, these results suggest that expression of An-
amorsin is completely dependent on cytokine stimulation
and, at least partially, regulated by Ras signaling in Ba/F3
cells. Next, we investigated the intracellular localization of
Anamorsin using immunofluorescence staining with an
anti-Anamorsin mAb. As shown in Fig. 2 f, Anamorsin was
exclusively localized in the cytoplasm of Ba/F3 cells, re-
gardless of stimulation with IL-3.
Generation of Anamorsin-null Mice. To assess in vivo
roles of Anamorsin, we tried to generate Anamorsin-null
(Anamorsin / ) mice. We constructed a targeting vector,
in which the first exon was replaced by the neomycin-
resistant cassette (a positive selection marker). The vector
also included diphtheria toxin as a negative selection marker
Figure 3. Targeted disruption of the murine An-
amorsin locus. (a) Partial restriction map of the
murine Anamorsin locus and the targeting con-
struct. The first to fifth exons of Anamorsin gene
are indicated as closed boxes in the top diagram.
K, KpnI; S, SpeI; Sa, SacI; Sm, SmaI; X, XhoI.
(b) Southern blot analysis was preformed with
genomic DNA extracted from tails of embryos by
hybridizing with a 5  flanking probe. The wild-type
allele is detected as a 5-kb SacI fragment and the
targeted allele as a 13-kb SacI fragment. (c) PCR
analysis was performed with primer pairs  /  and
 / . Genomic DNA from the wild-type allele
yields a 310-bp fragment with a primer pair  / ,
and that from the targeted allele yields a 730-bp
fragment with a primer pair  / . (d) Western blot
analysis was performed on total cellular lysates
obtained from limb of embryos with the indicated
genotypes using an anti-Anamorsin mAb.
Table I. Genotypes of Embryos from Timed Pregnancies
Stage AM   a AM    AM    Total No.
E10.5 6 17 5 28
E12.5 7 14 4 25
E14.5 17 68 16 (3b) 101 (3b)
E16.5 15 16 11 (4b) 42 (4b)
E18.5 12 32 9 (4b) 53 (4b)
At birth 15 45 6 (6c) 66 (6c)
aAM, Anamorsin.
bNumber of embryos absorbed in uterus.
cNumber of dead babies.Shibayama et al. 587
(Fig. 3 a). The targeting vector was introduced into an em-
bryonic stem (ES) cell line R1 by electroporation and
transfected cells were cultured with 150  g/ml G418. We
confirmed homologous recombination in selected ES cell
lines by Southern blot and PCR analyses. As expected from
Fig. 3 a, the wild-type allele was detected as a 5-kb SacI
fragment in Southern blot analysis with a 5  flanking probe,
whereas the targeted allele was detected as a 13-kb SacI
fragment (unpublished data). Also, in PCR analyses, the
310-bp fragment was amplified from the wild-type allelic
genomic DNA with a primer pair  / , whereas the 730-
bp fragment was amplified from the targeted allelic geno-
mic DNA with a primer pair  /  (unpublished data). To
generate chimeras, we injected three ES cell lines that were
confirmed to contain the homologous recombination into
blastocysts of C57BL/6J mice. Male offspring with a high
degree of chimerism were crossed with C57BL/6J females
to generate Anamorsin /   mice. Genotyping was per-
formed by Southern blot and PCR analyses using tail- and
embryo-derived DNA (Fig. 3, b and c). Finally, we con-
firmed that expression of Anamorsin protein in the limb
was partially reduced in Anamorsin /  embryos and com-
Figure 4. Phenotypes of
Anamorsin (AM) /   embryos,
spleens, and FLs. (a) E16.5 em-
bryos of Anamorsin /  and the
littermate control are shown.
(b) The spleens (arrows) with
stomach of Anamorsin /   and
Anamorsin /  mice at birth are
shown. (c) Transverse sections
of FL at E14.5 obtained from
Anamorsin /  (top) or Anamor-
sin /   (bottom) embryos were
stained with hematoxylin and
eosin for histological examina-
tion (left) and with TUNEL to
detect apoptotic cells (right).
Apoptotic cells are stained with
brown in this TUNEL assay.
 400. (d) Cell suspensions iso-
lated from Anamorsin /   (top)
and Anamorsin /  (bottom) FL
cells at E14.5 were stained with
anti–Ter-119 and annexin V,
and subjected to flow cytometric
analysis. (e) The proportions of
CD34  c-kit , CD34low CD44high,
and Ter-119   c-kit   cells in
Anamorsin /  and Anamorsin / 
FL cells at E14.5. Cell suspen-
sions isolated from Anamorsin / 
(top) and Anamorsin /  (bottom)
FL cells at E14.5 were stained
with anti–c-kit, anti-CD34, anti-
CD44, or anti–Ter-119, and sub-
jected to flow cytometric analysis.A Novel Antiapoptotic Molecule Anamorsin 588
pletely lost in Anamorsin /  embryos by Western blot
analysis using an anti-Anamorsin mAb (Fig. 3 d).
Anamorsin-null Mice Are Lethal at Late Gestation Due to the
Defect of Hematopoiesis. Genotypic analysis of embryos
from Anamorsin /   mice intercrosses revealed that
Anamorsin /  embryos began to die between E12.5 and
E14.5. The rate of dead Anamorsin /  embryos increased
after E14.5 (0% until E12.5, 18.8% at E14.5, 36.4% at
E16.5, and 44.4% at E18.5) and all Anamorsin /  mice
died at birth, suggesting that Anamorsin /  mice expire in
late gestation (Table I). Anamorsin /   embryos were
smaller in body size than Anamorsin /  embryos, whereas
Anamorsin /   embryos displayed phenotypes similar to
Anamorsin /  embryos (Fig. 4 a). Despite no significant
difference in the formation of blood islands in yolk sacs, the
FLs and spleens of Anamorsin /  embryos were remarkably
smaller than those of Anamorsin /  embryos. The size of
FL of Anamorsin /  embryos was about one third of that
of Anamorsin /  embryos, and the spleen of Anamorsin / 
embryos appeared scarce (Fig. 4 b). Furthermore,
Anamorsin /  embryos later than E14.5 looked anemic
(Fig. 4 a). Anamorsin /  embryos at E18.5 showed nearly
half of RBCs, hemoglobin, and hematocrit in the periph-
eral blood (RBC: 365   50.8, 335.5   50.6, and 210  
67.0 104/mm3; hemoglobin: 11.7   1.5, 10.6   1.3, and
6.7   2.3 g/dl; hematocrit: 39.7   5.8, 37.8   5.3, and
26.3   7.6% in Anamorsin /  [n   10], Anamorsin / 
[n     22], and Anamorsin /  [n     8] embryos, respec-
tively). Moreover, RBCs of Anamorsin /  embryos were
macrocytic (mean corpuscular volume in Anamorsin / ,
Anamorsin / , and Anamorsin /  embryos were 108.8  
4.3, 113.1   9.5, and 128.2   16.6, respectively). In addi-
tion to defects in hematopoietic organs, the heart walls of
Anamorsin /   embryos were thinner than those in
Anamorsin /  or Anamorsin /  embryos, whereas Ana-
morsin /  embryos displayed no apparent macroscopic or
histological abnormalities in other organs (not depicted). It
was unlikely that the abnormality in the heart walls caused
death in Anamorsin /  embryos.
Erythroid Cells Undergo Apoptosis in the FL of Anamorsin / 
Mice. To clarify the mechanism of anemia seen in
Anamorsin /  embryos, we analyzed the FL, the main he-
Figure 5. Anamorsin /   erythroid progenitors could
not differentiate in vivo and in vitro. (a and b) Cell suspen-
sions isolated from Anamorsin (AM) /  and Anamorsin / 
FL at E16.5 were subjected to cytospin centrifugation,
stained with May-Grunwald-Giemsa, and analyzed under
light microscopy.  1,000 (a). The number of erythroid
cells at each maturation stage was counted (b). (c and d)
104  FL cells at E14.5 obtained from Anamorsin / ,
Anamorsin / , and Anamorsin /  mice were cultured in
the methylcellulose containing SCF, IL-3, IL-6, and EPO,
and the number of hematopoietic colonies were counted
after 8-d cultures (c). Also, 105 FL cells at E14.5 were cul-
tured with SCF and EPO for 8 d, and the number of
BFU-E colonies was counted (d).Shibayama et al. 589
matopoietic organ of the late embryonic stage (28). The
number of morphologically identifiable small-sized ery-
throid cells (erythroblasts) with condensed chromatin nucleus
was apparently reduced in FL of Anamorsin /  embryos
compared with that of controls (Fig. 4 c). Furthermore,
erythroblasts were larger in Anamorsin /  embryos than in
Anamorsin /  embryos, and more mature erythroblasts (i.e.,
polychromatic and orthochromatic erythroblasts) markedly
decreased in Anamorsin /  embryos (Fig. 5, a and b). In ad-
dition, TUNEL assays showed that a substantial fraction of
FL cells were apoptotic (stained by brown) at E14.5 in
Anamorsin /  embryos, whereas these apoptotic cells were
hardly detected in Anamorsin /  embryos (Fig. 4 c). To de-
termine which type of cells undergo apoptosis, we per-
formed flow cytometric analysis using Anamorsin /  and
Anamorsin /  FL cells at E14.5. Although annexin V 
apoptotic cells were scarcely (only 0.5%) detected in
Anamorsin /  FL cells, 60.2% of isolated cells were positive
for annexin V in Anamorsin /  FL (Fig. 4 d). Most impor-
tantly, almost all of these apoptotic cells were Ter-119 
erythroid cells, but not Ter-119  cells, mainly composed
from hepatocytes (Fig. 4 d). Furthermore, although the cell
number of Anamorsin /  FL cells at E14.5 was approxi-
mately one third of Anamorsin /  FL cells (unpublished
data), the proportions of CD34   c-kit   cells, CD34low
CD44high cells, or Ter-119  c-kit  cells in Anamorsin /  FL
cells at E14.5 was two to four times higher than those in
Anamorsin /   FL cells (CD34   c-kit , 9.6 vs. 2.3%;
CD34low CD44high, 15.0 vs. 7.8%; Ter-119  c-kit , 12.5 vs.
5.0%; Fig. 4 e), indicating that neither the absolute number
of hematopoietic stem/progenitor cells (CD34  c-kit  or
CD34low CD44high) nor that of very immature proerythro-
blasts (Ter-119  c-kit ) decreased in Anamorsin /  FL.
Based on these data, it was speculated that immature he-
matopoietic cells of Anamorsin /  mice may succumb to
apoptosis and fail to attain terminal differentiation.
Colony Assays of the Anamorsin-null FL Cells. Next, we
examined whether hematopoietic stem/progenitor cells of
Anamorsin /  FL cells could survive, proliferate, and dif-
ferentiate in response to cytokines in vitro. When E14.5
Anamorsin / , Anamorsin / , or Anamorsin /  FL cells
were cultured in methylcellulose with the combination of
cytokines SCF, IL-3, IL-6, and EPO, the number of my-
eloid (granulocyte/macrophage and granulocyte) colonies
formed from Anamorsin /  FL cells was one third to one
fourth of those formed by Anamorsin /  FL cells. Notably,
Anamorsin /  FL cells gave rise to little or no mixed (my-
eloid/erythroid) or erythroid colonies, whereas such colo-
nies developed from Anamorsin /  and Anamorsin /  FL
cells (Fig. 5 c). Furthermore, BFU-E colonies did not de-
velop when E14.5 Anamorsin /  FL cells were cultured
with SCF and EPO (Fig. 5 d). These results suggest that
Anamorsin is essential for cytokine-dependent survival and
growth of hematopoietic stem/progenitor cells in vitro, es-
pecially those of erythroid lineage.
The Expression of Jak2 and Bcl-xL mRNA Was Down-regu-
lated in Anamorsin-null FL Cells. To characterize the anti-
apoptotic function of Anamorsin, we compared gene ex-
pression profiles between Anamorsin /  and Anamorsin / 
FL cells at E14.5 using a cDNA microarray. Among 4289
genes, including Bcl-2 family, caspases, cytokines, and sig-
nal transduction molecules, 184 genes were significantly
down-regulated and 40 were up-regulated in Anamorsin / 
FL. Among apoptosis-related genes, Bcl-xL and Jak2 were
down-regulated most significantly. We also confirmed that
expression of these two molecules was decreased in
Anamorsin /  FL cells compared with Anamorsin /  FL
cells by semiquantitative RT-PCR assays (Fig. 6 and Ta-
ble S1, available at http://www.jem.org/cgi/content/full/
jem.20031858/DC1).
Discussion
We have identified a novel antiapoptotic molecule, An-
amorsin, by using expression cloning with the cytokine-
independent subline Ba/F3-Ad. Although Anamorsin was
constitutively expressed in Ba/F3-Ad, its expression was
completely dependent on cytokine stimulation in Ba/F3
cells. It has been reported that IL-3, TPO, and SCF simul-
taneously activate the Ras/Raf/MEK/ERK pathway,
(Ras)/PI3K/Akt pathway, and STATs in Ba/F3 cells, and
that each of these signaling pathways can transmit antiapop-
totic signals from these cytokines (5, 6). Among these path-
ways, cytokine-activated Ras was involved, at least par-
tially, in the induction of Anamorsin. Although expression
of Anamorsin mRNA was supposed to be transcriptionally
regulated by cytokine stimulation, this expression was only
detectable at relatively late phases (from after 3 h), suggest-
ing that this induction is not an immediate early response.
Figure 6. RT-PCR analysis on the expression of Jak2 and Bcl-xL
mRNA in Anamorsin / , Anamorsin / , and Anamorsin /  FL cells.
Total RNA was isolated from E14.5 Anamorsin / , Anamorsin / , and
Anamorsin /  FL cells. 1.5  g total RNA was reverse transcribed to first
strand cDNA and subjected to PCR reactions. After the indicated cycles
of PCR reaction, PCR products were electrophoresed on agarose gels
and visualized with ethidium bromide staining.A Novel Antiapoptotic Molecule Anamorsin 590
Therefore, it is important to identify the molecule(s) that
connects Ras signals to expression of Anamorsin. It is also
necessary to examine whether other signaling pathways
such as STATs and PI-3K/Akt pathway might contribute
to induction of Anamorsin.
Anamorsin expression profiles showed that besides he-
matopoietic organs, Anamorsin was abundantly expressed
in liver, heart, and skeletal muscle. Because Anamorsin
was expressed in heart tissue, we compared hearts of
Anamorsin / , Anamorsin / , and Anamorsin /   em-
bryos, and found that heart walls of Anamorsin /  embryos
were thinner than those of Anamorsin /  or Anamorsin / 
mice. These results suggest that cells in these organs might
also receive cytokine stimulation and Anamorsin might
play some roles in cell survival of these cells. In fact, hepa-
tocyte growth factor acts as a crucial regulator of cell
growth and survival for hepatocytes (29), IL-6–type cyto-
kines (i.e., cardiotrophin-1, leukemia inhibitory factor, and
oncostatin M) for cardiac myocytes (30), and insulin-like
growth factor 1, leukemia inhibitory factor, and hepatocyte
growth factor for skeletal muscle cells (31). Therefore, it
might be interesting to investigate whether expression of
Anamorsin is also regulated by these growth factors in non-
hematopoietic cells. In contrast to hematopoietic cells and
cardiac myocytes, however, FL hepatocytes did not un-
dergo apoptosis. Also, no apparent abnormality was de-
tected in skeletal muscle of Anamorsin /  mice. These
findings suggest that the antiapoptotic roles of Anamorsin
might be replaced by other molecule(s) in these cells. Fur-
thermore, it is possible that Anamorsin might be a member
of a new family of proteins and other family members
might exist in these tissues.
Although expression of Anamorsin was detectable in the
early stage of embryos, Anamorsin was not required for
survival and development of early embryos. Moreover,
primitive hematopoiesis in the yolk sac of Anamorsin / 
embryos seemed normal as judged from its histology. In
contrast, Anamorsin /  erythroid progenitor cells in FL
could not proliferate or differentiate in response to cyto-
kine stimulation in colony assays, and underwent apoptosis
after the basophilic erythroblast stage in vivo. However,
Anamorsin did not affect transcription of  y2-globin (em-
bryonic-type),   -major-globin (adult-type), or  -globin
(embryonic- and adult-type) because all these globins were
normally expressed in Anamorsin /  FL erythrocytes (un-
published data). From these data, it was assumed that in
spite of its essential role as a survival factor, Anamorsin
would not be involved in differentiation of erythrocytes.
We speculate that the main cause of death in
Anamorsin /  embryos was anemia because we could not
find severe abnormalities in any organs except FL and
spleen. By generating KO mice, a number of molecules
were shown to be required for primitive and/or definitive
hematopoiesis: cytokines and their receptors, EPO/EPO
receptor (3), Angiopoietin-1/Tie-2 (32), and Flk1 (VEGF2
receptor; reference 33); signal transduction molecules, Jak2
(34) and p38 MAPK (35); transcription factors, c-Myb
(36), GATA-1 (37), GATA-2 (38), GATA-3 (39), FOG-1
(40), AML-1 (41), SCL (42), LMO-2 (43), CBF  (44), and
EKLF (45); Bcl-2 family members, Bcl-xL (46) and
DNaseII (47). As was seen in Anamorsin /  mice, defects
in Angiopoietin-1, Jak2, p38 MAPK, c-Myb, GATA-3,
AML-1, CBF , EKLF, Bcl-xL, or DNaseII genes dis-
rupted definitive hematopoiesis but not primitive hemato-
poiesis. To determine which molecule is responsible for the
observed antiapoptotic effects of Anamorsin, it might be
useful to measure expression levels of these molecules in
Anamorsin /  mice. At present, we have found that ex-
pression of Jak2 and Bcl-xL was down-regulated in
Anamorsin /  mice by using cDNA microarray and RT-
PCR analyses. Because the Jak2/Stat5 pathway was re-
ported to regulate expression of Bcl-xL (15, 16, 48), it was
speculated that Jak2 might be a primary mediator of the an-
tiapoptotic effects of Anamorsin. To examine this possibil-
ity, it would be effective to recover Jak2 and/or Bcl-xL ex-
pression in Anamorsin /  hematopoietic cells in in vitro
and in vivo assays.
In this study, we have shown that Anamorsin is a critical
molecule in cytokine-dependent cell survival of hematopoi-
etic cells. In addition, our preliminary studies suggested that
Anamorsin expression may not only protect cells against cy-
tokine withdrawal, but also against other apoptotic stimuli
because Anamorsin-expressing Ba/F3 cells were less suscep-
tible to apoptosis after treatment with etoposide,   radia-
tion, or staurosporine than IL-3–starved Ba/F3 cells in
which Anamorsin expression was scarcely observed. Further
studies on Anamorsin would indubitably reveal a new
mechanism underlying antiapoptotic effects of hematopoi-
etic growth factors and might be useful to establish novel
therapeutic strategies to correct ineffective hematopoiesis.
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